“We are developing innovative stem cell-based therapeutics to treat severe life-threatening diseases, where effective treatment is lacking or is insufficient”

Amniotics is now listed on NASDAQ First North Growth

The Amniotics family was gathered to celebrate the first day of trading on the 6th of July 2021

Unique Technology

Amniotic's platform enables the extraction of Mesenchymal Stem Cells (MSC) from amniotic fluid, which is recovered from healthy voluntary donors in connection with planned caesarean sections

Read more

Pipeline

Amniotics has a project portfolio where the same technology and methodology can be applied for various indications

Read more

Donors

Our procedure for collecting term amniotic fluid from voluntary healthy donors is performed at full-term planned caesarean deliveries

Read more

Collaborate with us

Read more

Use our GMP facility

Amniotics is a technology and service provider to Universities, Hospitals, and the Biopharmaceutical industry.

Advance our pipeline

Amniotics is looking to establish strategic partnerships with researchers and companies to accelerate the development of our stem-cell-based therapies to the benefit of patients. See our pipeline here.